Literature DB >> 30870538

How do these 3 diabetes agents compare in reducing mortality?

Jennifer Martini1, Catherine L Coe1, Anne Mounsey1.   

Abstract

A meta-analysis reveals that there may be advantages associated with SGLT-2 inhibitors and GLP-1 agonists that are not associated with DPP-4 inhibitors.

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30870538      PMCID： PMC6484967     

Source DB:  PubMed          Journal:  J Fam Pract        ISSN： 0094-3509            Impact factor:   0.493


  3 in total

1.  CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2018 EXECUTIVE SUMMARY.

Authors:  Alan J Garber; Martin J Abrahamson; Joshua I Barzilay; Lawrence Blonde; Zachary T Bloomgarden; Michael A Bush; Samuel Dagogo-Jack; Ralph A DeFronzo; Daniel Einhorn; Vivian A Fonseca; Jeffrey R Garber; W Timothy Garvey; George Grunberger; Yehuda Handelsman; Irl B Hirsch; Paul S Jellinger; Janet B McGill; Jeffrey I Mechanick; Paul D Rosenblit; Guillermo E Umpierrez
Journal:  Endocr Pract       Date:  2018-01-17       Impact factor: 3.443

Review 2.  Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis.

Authors:  Sean L Zheng; Alistair J Roddick; Rochan Aghar-Jaffar; Matthew J Shun-Shin; Darrel Francis; Nick Oliver; Karim Meeran
Journal:  JAMA       Date:  2018-04-17       Impact factor: 56.272

3.  Evaluating the quality of evidence from a network meta-analysis.

Authors:  Georgia Salanti; Cinzia Del Giovane; Anna Chaimani; Deborah M Caldwell; Julian P T Higgins
Journal:  PLoS One       Date:  2014-07-03       Impact factor: 3.240
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.